– BSI-082 is a fully human anti-SIRPα antagonistic monoclonal antibody with potential broad combo therapies for the treatment of hematologic and solid tumors NEWARK, Del. and NANJING, China, Jan. 24, 2024 /PRNewswire/ — Biosion USA, Inc. (Biosion), a global clinical-stage R&D…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.